{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:34:03Z","timestamp":1773916443795,"version":"3.50.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.beha.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,7,21]],"date-time":"2013-07-21T01:45:33Z","timestamp":1374371133000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["New developments in parenteral anticoagulation for arterial and venous thromboembolism"],"prefix":"10.1016","volume":"26","author":[{"given":"Nick","family":"van Es","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Bleker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry R.","family":"B\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2013.07.010_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beha.2013.07.010_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1749-6632.1981.tb29770.x","article-title":"Structural studies on a biologically active hexasaccharide obtained from heparin","volume":"370","author":"Choay","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beha.2013.07.010_bib3","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.beha.2013.07.010_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2013.07.010_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1538-7836.2007.02500.x","article-title":"The central role of thrombin in hemostasis","volume":"5","author":"Crawley","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF01825055","article-title":"\u00dcber den die Blutgerinnung aufhebenden Bestandteil des medizinischen Blutegels","volume":"49","author":"Franz","year":"1903","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.beha.2013.07.010_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1073\/pnas.83.4.1084","article-title":"Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis","volume":"83","author":"Harvey","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2013.07.010_bib8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.1999.01532.x","article-title":"Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment","volume":"106","author":"Huhle","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2013.07.010_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM199711063371901","article-title":"A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement","volume":"337","author":"Eriksson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/s-0038-1656063","article-title":"Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group","volume":"77","author":"Schiele","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2106\/00004623-199703000-00002","article-title":"Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement","volume":"79","author":"Eriksson","year":"1997","journal-title":"J Bone Jt Surg Am"},{"key":"10.1016\/j.beha.2013.07.010_bib13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators","volume":"335","author":"GUSTO-investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199509213331203","article-title":"A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators","volume":"333","author":"Serruys","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial","volume":"353","author":"OASIS-2-investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","article-title":"Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range","volume":"96","author":"Greinacher","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.07.010_bib18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/j.1538-7836.2005.01623.x","article-title":"Lepirudin in patients with heparin-induced thrombocytopenia\u2013results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3","volume":"3","author":"Lubenow","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib19","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1016\/S0021-9258(18)81848-8","article-title":"Anticoagulant activity of synthetic hirudin peptides","volume":"264","author":"Maraganore","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2013.07.010_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V75.2.399.bloodjournal752399","article-title":"Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin","volume":"75","author":"Jakubowski","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.07.010_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCRESAHA.112.264903","article-title":"Translational success stories: development of direct thrombin inhibitors","volume":"111","author":"Coppens","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.beha.2013.07.010_bib22","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2013.07.010_bib23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beha.2013.07.010_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beha.2013.07.010_bib25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib26","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib27","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib29","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","volume":"110","author":"Patti","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/CIRCINTERVENTIONS.112.968966","article-title":"Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry","volume":"5","author":"Hibbert","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.beha.2013.07.010_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjcard.2012.03.051","article-title":"Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention","volume":"110","author":"Bertrand","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib33","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib34","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beha.2013.07.010_bib35","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beha.2013.07.010_bib36","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beha.2013.07.010_bib37","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2005.10.049","article-title":"Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study","volume":"131","author":"Smedira","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.beha.2013.07.010_bib38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","article-title":"A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study","volume":"131","author":"Dyke","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.beha.2013.07.010_bib39","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.90.5.2385","article-title":"Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery","volume":"90","author":"Ginsberg","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1055\/s-0038-1648907","article-title":"Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis","volume":"72","author":"Ginsberg","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.athoracsur.2007.04.007","article-title":"Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four\/heparin antibodies","volume":"84","author":"Dyke","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.beha.2013.07.010_bib42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.beha.2013.07.010_bib43","first-page":"611","article-title":"The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results","volume":"15","author":"Mahaffey","year":"2003","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/0006-291X(81)91279-1","article-title":"Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion","volume":"101","author":"Okamoto","year":"1981","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.beha.2013.07.010_bib45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib46","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","article-title":"Argatroban anticoagulation in patients with heparin-induced thrombocytopenia","volume":"163","author":"Lewis","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2013.07.010_bib47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01064381","article-title":"Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban","volume":"2","author":"Matsuo","year":"1995","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.beha.2013.07.010_bib48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0735-1097(93)90222-M","article-title":"Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris","volume":"21","author":"Gold","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/A:1026591023462","article-title":"Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study","volume":"10","author":"Vermeer","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.beha.2013.07.010_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00133080","article-title":"Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study","volume":"3","author":"Herrman","year":"1996","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.beha.2013.07.010_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1055\/s-2007-996131","article-title":"Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis","volume":"23","author":"Kobayashi","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.beha.2013.07.010_bib52","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1161\/01.STR.0000131549.20581.ba","article-title":"Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study","volume":"35","author":"LaMonte","year":"2004","journal-title":"Stroke"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2013.07.010_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003088-200241002-00002","article-title":"Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins","volume":"41","author":"Paolucci","year":"2002","journal-title":"Clin Pharm"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2013.07.010_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","volume":"41","author":"Donat","year":"2002","journal-title":"Clin Pharm"},{"key":"10.1016\/j.beha.2013.07.010_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","article-title":"Fondaparinux - data on efficacy and safety in special situations","volume":"129","author":"Nagler","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.beha.2013.07.010_bib56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/13543784.11.3.397","article-title":"Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent","volume":"11","author":"Walenga","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.beha.2013.07.010_bib57","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.0000038501.87442.02","article-title":"Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers","volume":"106","author":"Bijsterveld","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib58","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib59","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib60","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib61","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.beha.2013.07.010_bib63","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.beha.2013.07.010_bib64","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.beha.2013.07.010_bib65","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.beha.2013.07.010_bib66","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.beha.2013.07.010_bib67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.7326\/0003-4819-140-11-200406010-00007","article-title":"Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial","volume":"140","author":"B\u00fcller","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2013.07.010_bib68","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","author":"B\u00fcller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib69","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib70","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib71","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.beha.2013.07.010_bib72","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib73","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib74","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMct1206642","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Kelton","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib75","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/j.1538-7836.2011.04487.x","article-title":"Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series","volume":"9","author":"Warkentin","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib76","first-page":"1028","article-title":"Idraparinux sodium. Sanofi-Aventis","volume":"7","author":"Ma","year":"2004","journal-title":"IDrugs"},{"key":"10.1016\/j.beha.2013.07.010_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00228-008-0463-0","article-title":"Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials","volume":"64","author":"Harenberg","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.beha.2013.07.010_bib78","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"Buller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1538-7836.2010.03746.x","article-title":"Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion","volume":"8","author":"Paty","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1538-7836.2010.04100.x","article-title":"Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis","volume":"9","author":"EQUINOX-investigators","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(11)61505-5","article-title":"Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial","volume":"379","author":"B\u00fcller","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.07.010_bib83","doi-asserted-by":"crossref","first-page":"e120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.beha.2013.07.010_bib84","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/S0735-1097(03)00478-9","article-title":"Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor\/factor VIIa complex, in patients undergoing elective coronary angioplasty","volume":"41","author":"Moons","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/hc2601.091386","article-title":"Dose-response study of recombinant factor VIIa\/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement","volume":"104","author":"Lee","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib86","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2007.02.065","article-title":"Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial","volume":"49","author":"Giugliano","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.beha.2013.07.010_bib87","series-title":"Safety study of recombinant NAPc2 to prevent tumor progression and metastases in metastatic colon cancer","author":"National Institutes of Health Clinical Center","year":"2007"},{"key":"10.1016\/j.beha.2013.07.010_bib88","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.109.927756","article-title":"First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention","volume":"122","author":"Cohen","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib89","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.107.745687","article-title":"Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease","volume":"117","author":"Chan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.beha.2013.07.010_bib90","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment","volume":"8","author":"L\u00f6wenberg","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib91","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.07.010_bib92","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1538-7836.2012.04701.x","article-title":"Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE","volume":"10","author":"Lassen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.beha.2013.07.010_bib93","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2013.07.010_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2012.10.001","volume":"164","author":"Steg","year":"2012","journal-title":"Am Heart J"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T21:20:49Z","timestamp":1646169649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1521692613000315"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.07.010","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in parenteral anticoagulation for arterial and venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}